The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...

Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis ...

Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss ...

The Ferrari deal is expected to be the largest of a clutch of block trades this week, including a Sfr2.6bn (€2.8bn) block in ...

The investment company of the Sandoz family, Emasan AG, has divested a substantial portion of its holdings in Swiss pharmaceutical giant Novartis. Through an accelerated bookbuilding process, 26.5 ...

Analysts have suggested its financial troubles could make a sale more difficult, as could untangling Sandoz from Novartis' broader manufacturing operations, although the launch of new biosimilars ...

The Sandoz Family Foundation, Novartis's second-largest shareholder with a 4.1% stake, has announced plans to sell a substantial portion of its holdings in the pharmaceutical giant. This strategic ...

Emasan AG, a subsidiary of the Sandoz Family Foundation, has initiated a public offering of approximately 26.5 million shares ...

(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.